Kristian et al. reported in a study investigating triple-negative breast cancer xenografts in mice that 18F-FDG-PET can be applied for the assessment of therapy effects of the anti-VEGF antibody bevacizumab as early as 24h after first treatment [42]. The gene discussed is VEGFA; the disease is triple-negative breast carcinoma.